Zepbound vs Mounjaro is simple chemically. They both contain tirzepatide. The difference is the FDA label, insurance pathway, and reason your clinician is prescribing it.
🔑 Key Takeaways
- Zepbound and Mounjaro both contain tirzepatide, a dual GLP-1 plus GIP receptor agonist from Eli Lilly. The active ingredient is identical
- Zepbound is approved for chronic weight management (adults with BMI 30+ or 27+ with comorbidity) and for moderate to severe obstructive sleep apnea in adults with obesity
- Mounjaro is approved for type 2 diabetes as an adjunct to diet and exercise
- The dosing schedule is identical for both: 2.5 mg → 5 → 7.5 → 10 → 12.5 → 15 mg weekly, with a target maintenance at 10, 12.5, or 15 mg
- Side effects are identical because the molecule is identical. GI effects dominate (nausea, diarrhea, constipation, vomiting) and fade with slow titration
- Zepbound is available in both pre-filled pens (KwikPen) and single-dose vials through LillyDirect at $499/month flat-rate
- Mounjaro is available as pre-filled pens and vials. Cost is typically covered by insurance for T2D
- You cannot use Mounjaro interchangeably with Zepbound for weight loss or vice versa, even though they are the same molecule. The brand you fill determines insurance coverage
This page answers the full Zepbound vs Mounjaro decision: what makes them FDA-different despite being chemically identical, the weight-loss and diabetes data, dosing, side effects, cost (including the LillyDirect vial program), insurance coverage, and who should pick which.
Zepbound vs Mounjaro Quick Answer
| Question | Answer |
|---|---|
| Are they the same drug? | Yes. Both contain tirzepatide. |
| What is Zepbound for? | Chronic weight management and moderate to severe OSA in adults with obesity. |
| What is Mounjaro for? | Type 2 diabetes. |
| Is dosing different? | No meaningful difference: both use once-weekly tirzepatide titration. |
| Which one should you ask about? | The one that matches your diagnosis and insurance coverage. |
What's the Difference Between Zepbound and Mounjaro?
Nothing inside the pen. Everything outside it.
Both drugs are tirzepatide, a once-weekly dual agonist that activates the GLP-1 receptor and the GIP receptor. The molecule is identical. The difference is FDA labeling: Mounjaro was the first brand approved (May 2022, for type 2 diabetes), and Zepbound followed in November 2023 specifically for chronic weight management, with an obstructive sleep apnea indication added in December 2024. Insurance plans treat them as separate drugs because the indications differ, even though they are chemically identical.
Zepbound vs Mounjaro: Specs Side-by-Side
| Zepbound | Mounjaro | |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly |
| FDA indication | Chronic weight management, obstructive sleep apnea | Type 2 diabetes |
| First FDA approval | November 2023 | May 2022 |
| Receptors | GLP-1 + GIP (dual agonist) | GLP-1 + GIP (dual agonist) |
| Dose range | 2.5 to 15 mg weekly | 2.5 to 15 mg weekly |
| Injection frequency | Once weekly | Once weekly |
| Pen options | KwikPen, single-dose vials (LillyDirect) | Pre-filled pen, vials |
| Avg weight loss | ~20.2% at 72 weeks (SURMOUNT-5) | ~15-20% (observed in T2D trials) |
| List price / month | ~$1,060 | ~$1,020 |
| Direct cash program | LillyDirect vials: $499/month flat | No dedicated cash program |
FDA-Approved Uses: Where They Differ
Zepbound approvals
- Chronic weight management: Adults with BMI 30+, or BMI 27+ with at least one weight-related condition (hypertension, dyslipidemia, type 2 diabetes, sleep apnea, cardiovascular disease)
- Obstructive sleep apnea (OSA): Added December 2024. First drug ever FDA-approved specifically for moderate to severe OSA in adults with obesity. A unique indication in the entire GLP-1 class
Mounjaro approvals
- Type 2 diabetes: As an adjunct to diet and exercise to improve glycemic control. Added to metformin, sulfonylureas, or insulin for combination therapy
- Not approved for weight loss, OSA, or cardiovascular risk reduction, despite documented benefits in each category
Mounjaro is sometimes prescribed off-label for weight loss when Zepbound is not available due to insurance or supply issues. Legal but adds a prior-authorization hurdle for insurance, since weight loss is not the indication.
How Zepbound and Mounjaro Work
Dual agonism explains why tirzepatide is stronger than semaglutide.
Tirzepatide binds two receptors at once: the GLP-1 receptor (like semaglutide, Wegovy, Saxenda, and the rest of the single-agonist class) and the GIP receptor. GIP is an incretin hormone released alongside GLP-1 after meals. Adding GIP receptor activation on top of GLP-1 activation produces a synergistic effect that boosts weight loss and HbA1c reduction beyond what GLP-1 alone achieves. This is why tirzepatide outperforms semaglutide in head-to-head trials.
Zepbound and Mounjaro each activate both receptors in exactly the same way. The mechanism is identical.
Weight Loss Data
Zepbound and Mounjaro produce similar weight loss per dose because they are the same molecule. The difference is the patient population studied.
- SURMOUNT-1 (Zepbound, 2022 NEJM): 22.5% average weight loss at 72 weeks with 15 mg in adults with obesity without T2D
- SURMOUNT-2 (Zepbound, 2023): 13.7% average weight loss at 72 weeks in adults with both obesity and T2D
- SURMOUNT-5 (2025 head-to-head): Zepbound 15 mg produced 20.2% average weight loss vs semaglutide 2.4 mg at 13.7% weight loss
- SURPASS program (Mounjaro): Weight loss in T2D patients ranged from 8 to 20% depending on dose, alongside large HbA1c reductions
Weight loss is slightly less in patients with T2D compared to those without T2D, a consistent pattern across the entire GLP-1 class. That is why the Zepbound trials reported higher averages than Mounjaro's.
Dosing: Identical for Both Drugs
Shared Tirzepatide Dose Schedule
- Weeks 1-4: 2.5 mg once weekly (starting dose)
- Weeks 5-8: 5 mg once weekly
- Weeks 9-12: 7.5 mg once weekly
- Weeks 13-16: 10 mg once weekly (a common maintenance dose)
- Weeks 17-20: 12.5 mg once weekly
- Week 21 onward: 15 mg once weekly (maximum dose)
Target maintenance dose is usually 10, 12.5, or 15 mg depending on how you respond and how well you tolerate GI side effects. The 15 mg dose produces the most weight loss but also the highest nausea and diarrhea rates. Many patients land at 10 mg with excellent results and manageable side effects.
Zepbound vs Mounjaro Side Effects
Identical, because it is the same molecule.
| Side effect | Frequency | Notes |
|---|---|---|
| Nausea | ~29% | Peaks in first 4 weeks, fades with continued use |
| Diarrhea | ~23% | Typically mild |
| Constipation | ~17% | Fiber, hydration, magnesium help |
| Vomiting | ~10% | During dose escalation |
| Decreased appetite | Common | Responsible for the weight loss |
| Injection site reaction | Variable | Rotate sites to minimize |
Both carry the identical boxed warning for medullary thyroid carcinoma and MEN2 family history. Both carry the same rare-but-serious risks: pancreatitis, gallbladder disease, kidney injury, hypersensitivity reactions, and possible diabetic retinopathy worsening in pre-existing cases. See our tirzepatide side effects guide for the full profile.
Cost and Insurance
| Option | Zepbound | Mounjaro |
|---|---|---|
| List price (cash) | ~$1,060/month | ~$1,020/month |
| Direct cash program | LillyDirect single-dose vial: $499/month flat rate | No dedicated cash program |
| Commercial insurance | $25-$250 copay, obesity PA required | $25-$200 copay, T2D PA standard |
| Medicare | KwikPen covered through GLP-1 Bridge starting July 2026 | Covered for T2D |
| Medicaid | Varies by state | Usually covered for T2D |
The LillyDirect single-dose vial at $499/month flat is the biggest 2026 cost innovation. Instead of paying more for higher doses (as typically happens with pen-based pricing), you pay the same monthly price whether you are on 2.5 mg or 15 mg. You draw your own dose from the vial with a syringe, which is a small learning curve but a major cost advantage.
Insurance Reality
Mounjaro is easier to get covered.
Mounjaro has been on the market for longer and has the T2D indication, which every commercial insurance plan covers with standard prior authorization. Medicare Part D covers it for T2D.
Zepbound requires weight-management prior authorization, which tends to include documented BMI, a weight-related comorbidity, evidence of prior lifestyle intervention, and sometimes a failed trial of a cheaper weight-loss medication first. Coverage is improving in 2026 as obesity is increasingly treated as a chronic disease, but it is still harder to get approved than Mounjaro.
The LillyDirect vial program at $499/month is the workaround when insurance denies Zepbound. It is not cheap, but it is predictable and flat-rate across all doses.
Who Should Pick Zepbound vs Mounjaro
Pick Zepbound if
- Your primary goal is weight loss and you qualify (BMI 30+, or 27+ with comorbidity)
- You have obstructive sleep apnea with obesity (Zepbound is the first and only drug FDA-approved for this)
- You are using LillyDirect cash vials ($499/month flat rate regardless of dose)
- You have commercial insurance that covers weight-management GLP-1s
- You want maximum weight loss without type 2 diabetes
Pick Mounjaro if
- You have type 2 diabetes (the primary FDA indication)
- Your insurance covers Mounjaro but not Zepbound, and weight loss is a secondary but welcome effect
- Your prescriber is navigating step therapy and needs to start with a T2D-indicated drug before escalating to Zepbound
For the broader comparison landscape, see our weight loss injections overview or the weight loss drugs reference.
Can You Switch Between Zepbound and Mounjaro?
Yes. The transition is seamless because the molecule is identical. Your prescriber matches the new-drug dose to the old-drug dose. If you are on Mounjaro 10 mg weekly, you switch to Zepbound 10 mg weekly with no titration reset. Allow 1 week between the last dose of the old brand and the first dose of the new one.
The common scenarios: starting on Mounjaro (easier insurance approval, T2D billing) and switching to Zepbound once a weight-management PA is approved. Or starting on Zepbound LillyDirect vials and switching to Mounjaro pens if the patient later develops T2D and gets new insurance coverage. Both directions are clinically routine.
Zepbound vs Mounjaro: What Changed in 2026
The Zepbound vs Mounjaro decision shifted in 2026 for three reasons. First, Zepbound now carries an FDA approval for moderate to severe obstructive sleep apnea in adults with obesity, the first drug ever approved for that condition. Mounjaro does not carry the OSA label even though it is the same molecule, which means insurance for OSA coverage requires Zepbound specifically. See our tirzepatide for sleep apnea deep dive for the data and prescribing details.
Second, the Medicare GLP-1 Bridge Program starts on July 1, 2026 and covers Zepbound KwikPen for eligible beneficiaries with obesity and a qualifying comorbidity at roughly $50 per month. Mounjaro remains covered under Medicare Part D for type 2 diabetes only. If you are 65 or older without diabetes, Zepbound becomes the practical choice.
Third, LillyDirect Self-Pay vials are now active for both brands at $349 to $499 per month depending on dose, but they are aimed at cash payers without commercial insurance. The single-dose vials require manual draw with a syringe rather than the KwikPen autoinjector, which is a tradeoff some patients accept for the lower price.
Switching Between Zepbound and Mounjaro
Because Zepbound and Mounjaro contain identical tirzepatide, switching between them is one of the simplest transitions in GLP-1 medicine. There is no titration reset, no washout that requires backtracking to a lower dose, and no pharmacokinetic concern. The clinician matches the new dose to the dose you were already on (5 mg Mounjaro becomes 5 mg Zepbound and so on) and the next weekly injection happens on the normal schedule.
The reason switches happen has more to do with insurance and labeling than pharmacology. Common scenarios include: a Mounjaro patient who lost enough weight to no longer meet the T2D coverage criteria and needs to move to Zepbound under a weight-management benefit, a Zepbound patient who develops type 2 diabetes and gets better A1C coverage under the Mounjaro label, or a sleep apnea patient whose payer requires Zepbound for the OSA indication.
One practical note: when switching, your pharmacy benefit may require a fresh prior authorization for the new brand, so build in two to three weeks of overlap if possible to avoid a missed dose. If you are weighing the broader weight-loss options instead of staying within the tirzepatide brands, see tirzepatide vs semaglutide and weight loss injections for full comparisons.